Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Whole-cell versus acellular pertussis priming for allergy prevention in infants
ACTRN12617000065392Phase 4Active, not recruiting
- Sponsor
- University of Sydney
- Start
- Mar 2018
- Modality
- Vaccines & Immunotherapeutics, Device-based Delivery → Drug Delivery Systems, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Tritanrix HepB/Hib, pertussis filamentous haemagglutinin and tetanus toxoid + diphtheria toxoid + acellular pertussis + inactivated poliovirus vaccine in food allergy, allergy and pertussis (2 arms), sponsored by University of Sydney. Primary endpoint: IgE-mediated food allergy by 12 months. Started Mar 2018; status: active, not recruiting.
02
Drugs
Tritanrix HepB/Hibpertussis filamentous haemagglutinintetanus toxoid + diphtheria toxoid + acellular pertussis + inactivated poliovirus vaccine
03
Conditions
food allergyallergypertussis
Beyond the preview
Go deeper on ACTRN12617000065392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000065392.